DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on December 1, 2006; DOI: 10.1124/dmd.106.013185


0090-9556/07/3503-325-327$20.00
DMD 35:325-327, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.013185v1
35/3/325    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Embrechts, M. J.
Right arrow Articles by Ekins, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Embrechts, M. J.
Right arrow Articles by Ekins, S.
SHORT COMMUNICATION

Classification of Metabolites with Kernel-Partial Least Squares (K-PLS)

Mark J. Embrechts, and Sean Ekins

Department of Decision Sciences and Engineering Systems, Rensselaer Polytechnic Institute, Troy, New York (M.J.E.); and GeneGo, Inc., St. Joseph, Michigan, and Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (S.E.)

Numerous experimental and computational approaches have been developed to predict human drug metabolism. Since databases of human drug metabolism information are widely available, these can be used to train computational algorithms and generate predictive approaches. In turn, they may be used to assist in the identification of possible metabolites from a large number of molecules in drug discovery based on molecular structure alone. In the current study we have used a commercially available database (MetaDrug) and extracted a fraction of the human drug metabolism data. These data were used along with augmented atom descriptors in a predictive machine learning model, kernel-partial least squares (K-PLS). A total of 317 molecules, including parent drugs and their primary and secondary (sequential) metabolites, were used to build these models corresponding to individual metabolism rules, representing the formation of discrete metabolites, e.g., N-dealkylation. Each model was internally validated to assess the capability to classify other molecules that were left out. Using receiver operator curve statistics models for N-dealkylation, O-dealkylation, aromatic hydroxylation, aliphatic hydroxylation, O-glucuronidation, and O-sulfation gave area under the curve values from 0.75 to 0.84 and were able to predict between 61 and 79% active molecules upon leave-one-out testing. This preliminary study indicates that K-PLS and possibly other similar machine learning methods (such as support vector machines) can be applied to predicting human drug metabolite formation in a classification manner. Improvements can be achieved using considerably larger datasets that contain more positive examples for the less frequently occurring metabolite rules, as well as the external evaluation of novel molecules.


Address correspondence to: Dr. Sean Ekins, ACT LLC, 601 Runnymede Ave., Jenkintown, PA 19046. E-mail ekinssean{at}yahoo.com, sekins{at}arnoldllc.com




This article has been cited by other articles:


Home page
BioinformaticsHome page
K. Fenner, J. Gao, S. Kramer, L. Ellis, and L. Wackett
Data-driven extraction of relative reasoning rules to limit combinatorial explosion in biodegradation pathway prediction
Bioinformatics, September 15, 2008; 24(18): 2079 - 2085.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.